within Pharmacolibrary.Drugs.ATC.B;

model B01AC16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.9166666666666666,
    adminDuration  = 600,
    adminMass      = 0.18,
    adminCount     = 1,
    Vd             = 0.185,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Eptifibatide is a cyclic heptapeptide antiplatelet drug, classified as a glycoprotein IIb/IIIa receptor antagonist. It is used to reduce the risk of acute cardiac ischemic events, such as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Eptifibatide is approved and in clinical use for this indication.</p><h4>Pharmacokinetics</h4><p>Mean pharmacokinetic parameters in adults with coronary artery disease undergoing PCI, male and female, typical intravenous administration.</p><h4>References</h4><ol><li><p>Alton, KB, et al., &amp; Patrick, JE (1998). Disposition of 14C-eptifibatide after intravenous administration to healthy men. <i>Clinical therapeutics</i> 20(2) 307–323. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(98)80094-5&quot;>10.1016/s0149-2918(98)80094-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9589822/&quot;>https://pubmed.ncbi.nlm.nih.gov/9589822</a></p></li><li><p>Van Tuyl, JS, et al., &amp; Hollis, IB (2019). Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety. <i>The Annals of pharmacotherapy</i> 53(7) 726–737. DOI:<a href=&quot;https://doi.org/10.1177/1060028018824640&quot;>10.1177/1060028018824640</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30646761/&quot;>https://pubmed.ncbi.nlm.nih.gov/30646761</a></p></li><li><p>Ostrowska, M, et al., &amp; Kubica, J (2014). Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. <i>Cardiology journal</i> 21(5) 458–464. DOI:<a href=&quot;https://doi.org/10.5603/CJ.a2014.0020&quot;>10.5603/CJ.a2014.0020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24526503/&quot;>https://pubmed.ncbi.nlm.nih.gov/24526503</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC16;
